Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study

Abstract Background Achieving clinical remission is a key therapeutic goal in rheumatoid arthritis (RA). While pivotal trials and early real-world studies have demonstrated the efficacy of upadacitinib (UPA), data on its impact as assessed by imaging remain limited. Here, we report the 48 weeks outc...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Andrea Picchianti Diamanti, Valentino Paci, Michele Maria Luchetti Gentiloni, Simonetta Salemi, Giorgio Sesti, Ilaria Anna Bellofatto, Caterina Baldi, Paolo Falsetti, Maria Sole Chimenti, Arianna D’Antonio, Gloria Crepaldi, Alen Zabotti, Ivan Giovannini, Marco Canzoni, Donatella Fiore, Gian Domenico Sebastiani, Chiara Scirocco, Carlo Perricone, Bruno Laganà, Annamaria Iagnocco
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2025-11-01
Rangatū:	Arthritis Research & Therapy
Ngā marau:	Clinical remission Ultrasonographic remission JAK inhibitors Upadacitinib
Urunga tuihono:	https://doi.org/10.1186/s13075-025-03671-z
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!